DUL:FRA
Alnylam Pharmaceuticals, Inc.
€207.60
arrow_upward
+0.92%(+1.90) 1D
Oct 19, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DUL...
Open
€207.00
High
€209.70
Low
€206.30
Mkt. cap
31.22B
Avg. vol.
23.00
Volume
0.00
52-wk high
€423.00
52-wk low
€173.50
No. of employees
2K
Open
€207.00
High
€209.70
Low
€206.30
Mkt. cap
31.22B
Avg. vol.
23.00
Volume
0.00
52-wk high
€423.00
52-wk low
€173.50
No. of employees
2K
News stories
From web sources and news partners
The Business Journals
·
3 days ago
Alnylam founder's new biotech lands $200M in upsized IPO
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEOYvonne Greenstreet
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorBiotechnology
Websitealnylam.com